Royalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by Analysts

Key Points

• Royalty Pharma has a consensus analyst rating of “Buy”, with all seven covering brokerages assigning buy ratings and an average 1-year target price of about $53.71.
• The company reported Q1 earnings of $1.30 per share, beating estimates, though revenue of $631 million came in below expectations.
• Royalty Pharma also announced a quarterly dividend of $0.235 per share, implying an annualized yield of 1.8%; meanwhile, insiders have been selling shares in recent months.

Shares of Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) have been assigned a consensus rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $53.7143.

A number of analysts have recently commented on the stock. Weiss Ratings raised shares of Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, May 1st. Morgan Stanley raised their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a report on Friday, April 10th. Citigroup lifted their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Wall Street Zen upgraded shares of Royalty Pharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 9th. Finally, The Goldman Sachs Group reissued a "buy" rating on shares of Royalty Pharma in a report on Thursday, February 12th.

Royalty Pharma Trading Down 1.0%

Royalty Pharma stock opened at $52.85 on Friday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. Royalty Pharma has a one year low of $32.15 and a one year high of $53.47. The stock has a market capitalization of $30.43 billion, a PE ratio of 35.95, a price-to-earnings-growth ratio of 1.47 and a beta of 0.40. The business's fifty day moving average is $48.31 and its 200 day moving average is $43.35.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million during the quarter, compared to analyst estimates of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, sell-side analysts predict that Royalty Pharma will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma's dividend payout ratio is 63.95%.

Insider Buying and Selling at Royalty Pharma

In related news, Director Gregory Norden sold 3,045 shares of the business's stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the sale, the director directly owned 191,803 shares in the company, valued at approximately $10,165,559. The trade was a 1.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 155,893 shares of company stock worth $7,512,360 in the last three months. 18.84% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. LM Advisors LLC purchased a new stake in shares of Royalty Pharma in the 4th quarter worth $26,000. Lloyd Advisory Services LLC. bought a new stake in Royalty Pharma during the fourth quarter valued at about $30,000. Smartleaf Asset Management LLC grew its holdings in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 790 shares during the period. Private Trust Co. NA increased its position in Royalty Pharma by 52.9% in the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 288 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Royalty Pharma by 173.4% in the first quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 437 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.